Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization

Mac E. Hadley, Robert T Dorr

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.

Original languageEnglish (US)
Pages (from-to)921-930
Number of pages10
JournalPeptides
Volume27
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Melanocortins
Skin
Melanocortin Receptors
Tanning
Cyclic Peptides
Peptides
Skin Neoplasms
Erectile Dysfunction
Clinical Trials
Hormones
Technology
Therapeutics
bremelanotide
Clinical Studies
melanotan-II

Keywords

  • Erectile dysfunction
  • Melanocortin
  • Melanocyte
  • Melanogenesis
  • Melanoma
  • POMC

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Melanocortin peptide therapeutics : Historical milestones, clinical studies and commercialization. / Hadley, Mac E.; Dorr, Robert T.

In: Peptides, Vol. 27, No. 4, 04.2006, p. 921-930.

Research output: Contribution to journalArticle

@article{d6f483b8f3524454b12cb0f04914b9c5,
title = "Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization",
abstract = "The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.",
keywords = "Erectile dysfunction, Melanocortin, Melanocyte, Melanogenesis, Melanoma, POMC",
author = "Hadley, {Mac E.} and Dorr, {Robert T}",
year = "2006",
month = "4",
doi = "10.1016/j.peptides.2005.01.029",
language = "English (US)",
volume = "27",
pages = "921--930",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Melanocortin peptide therapeutics

T2 - Historical milestones, clinical studies and commercialization

AU - Hadley, Mac E.

AU - Dorr, Robert T

PY - 2006/4

Y1 - 2006/4

N2 - The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.

AB - The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.

KW - Erectile dysfunction

KW - Melanocortin

KW - Melanocyte

KW - Melanogenesis

KW - Melanoma

KW - POMC

UR - http://www.scopus.com/inward/record.url?scp=33645407840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645407840&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2005.01.029

DO - 10.1016/j.peptides.2005.01.029

M3 - Article

C2 - 16412534

AN - SCOPUS:33645407840

VL - 27

SP - 921

EP - 930

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 4

ER -